Cisco’s Earnings And Guidance Meet Wall Street Forecasts
Cisco Systems (CSCO) has reported financial results and forward guidance that are largely inline with Wall Street forecasts.
The technology giant announced earnings per share of $0.99 U.S., which was slightly ahead of the $0.98 U.S. that had been expected.
Revenue in the period totaled $14.67 billion U.S., which was also just ahead of the $14.62 billion U.S. forecast on Wall Street. Sales were up 7.6% from a year earlier.
In terms of guidance, management called for $4 U.S. to $4.06 U.S. in earnings per share (EPS) and $59 billion U.S. to $60 billion U.S. in revenue for the current fiscal year.
Analysts had been looking for earnings of $4.03 U.S. a share and $59.53 billion U.S. in revenue.
In what was its fiscal fourth quarter, Cisco generated $7.63 billion U.S. in networking revenue, up 12% from last year. Analysts were looking for $7.34 billion U.S.
Cisco’s security revenue for the quarter totaled $1.95 billion U.S., up 9% year-over-year but trailing estimates of $2.11 billion U.S.
During the quarter, Cisco introduced switches and routers that can take on artificial intelligence (A.I.) workloads.
A.I. infrastructure orders from internet companies during the quarter totaled $800 million U.S.
Cisco’s sales pipeline for A.I. infrastructure from enterprises is in the hundreds of millions of dollars, according to the company.
CSCO stock is up 19% this year and trading at $70.27 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


